MESO

Mesoblast Ltd ADR

Feb 27 • 04:00PM ET

15.85

-1.07 -6.32 %

Healthcare • Biotechnology • Australia • NASD

Peers: BMRN SRPT IONS SGMO BLUE ALNY FATE TVRD CYTK KPTI

Index	-	P/E	-	EPS (ttm)	-0.85	Insider Own	-	Shs Outstand	129.03M	Perf Week	-6.10%
Market Cap	2.05B	Forward P/E	53.55	EPS next Y	0.30	Insider Trans	-	Shs Float	128.29M	Perf Month	-15.24%
Enterprise Value	2.01B	PEG	-	EPS next Q	0.01	Inst Own	3.25%	Short Float	2.10%	Perf Quarter	-1.31%
Income	-102.16M	P/S	118.90	EPS this Y	87.00%	Inst Trans	40.67%	Short Ratio	12.55	Perf Half Y	-1.67%
Sales	17.20M	P/B	3.40	EPS next Y	369.09%	ROA	-14.05%	Short Interest	2.69M	Perf YTD	-12.14%
Book/sh	4.67	P/C	12.66	EPS next 5Y	-	ROE	-18.96%	52W High	21.50 -26.28%	Perf Year	1.99%
Cash/sh	1.25	P/FCF	-	EPS past 3/5Y	14.16% 9.59%	ROIC	-15.28%	52W Low	9.61 64.93%	Perf 3Y	147.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	18.91% -11.49%	Gross Margin	32.93%	Volatility	3.26% 3.20%	Perf 5Y	-17.45%
Dividend TTM	-	EV/Sales	116.96	EPS Y/Y TTM	5.09%	Oper. Margin	-363.56%	ATR (14)	0.74	Perf 10Y	30.78%
Dividend Ex-Date	-	Quick Ratio	1.77	Sales Y/Y TTM	191.53%	Profit Margin	-593.86%	RSI (14)	38.63	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.99	EPS Q/Q	12.30%	SMA20	-6.21%	Beta	2.16	Target Price	28.68
Payout	-	Debt/Eq	0.21	Sales Q/Q	-5.35%	SMA50	-11.59%	Rel Volume	1.71	Prev Close	16.92
Employees	81	LT Debt/Eq	0.12	Earnings	Feb 26 AMC	SMA200	2.32%	Avg Volume	214.69K	Price	15.85
IPO	Jan 18, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	-31.22% -3.25%	Trades		Volume	366,524	Change	-6.32%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Upgrade	Jefferies	Hold → Buy
Jul-18-25	Downgrade	Jefferies	Buy → Hold
Dec-23-24	Downgrade	Jefferies	Buy → Hold
Sep-24-24	Upgrade	Maxim Group	Hold → Buy	$12
Aug-29-24	Upgrade	Jefferies	Hold → Buy
Jul-23-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $11
Aug-31-23	Upgrade	Jefferies	Hold → Buy
Aug-07-23	Downgrade	Maxim Group	Buy → Hold
Aug-04-23	Downgrade	William Blair	Outperform → Mkt Perform
Aug-04-23	Downgrade	Piper Sandler	Overweight → Neutral	$7 → $2
Mar-09-23	Initiated	William Blair	Outperform	$8
Dec-06-22	Downgrade	Jefferies	Buy → Hold
Sep-06-22	Initiated	Piper Sandler	Overweight	$7
Apr-07-21	Upgrade	Maxim Group	Hold → Buy	$18
Dec-22-20	Downgrade	Maxim Group	Buy → Hold
Dec-04-20	Downgrade	Chardan Capital Markets	Neutral → Sell	$7.50
Oct-22-20	Initiated	RBC Capital Mkts	Sector Perform	$12
Aug-14-20	Reiterated	Maxim Group	Buy	$16 → $22
May-28-20	Reiterated	H.C. Wainwright	Buy	$14 → $21
Jan-31-19	Resumed	H.C. Wainwright	Buy	$6.50

Show Previous Ratings

Feb-27-26 12:07AM	Mesoblast H1 Earnings Call Highlights (MarketBeat) -6.32%
Feb-26-26 07:42PM	Ryoncil Profits Underpinning Substantial Growth Pipeline (GlobeNewswire)
Feb-20-26 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-12-26 08:11AM	Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy (Benzinga) -7.70%
Feb-11-26 06:27PM	High Survival Rates With Ryoncil in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD (GlobeNewswire)
06:54PM	Loading…
Jan-28-26 06:54PM	Ryoncil Net Revenues Increase for the Quarter to US$30M (GlobeNewswire)
Jan-27-26 01:01PM	Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication (Benzinga)
Jan-26-26 06:45PM	Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment (GlobeNewswire)
Jan-20-26 01:33PM	FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain (Benzinga)
Jan-18-26 07:01PM	FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy (GlobeNewswire)
Jan-09-26 12:34PM	Mesoblast Stock Rises On Strong Year-Over-Year Growth In Ryoncil Sales (Benzinga) +5.49%
Jan-08-26 10:05PM	Markets in a Minute: Mesoblast, Alkane Resources shine (Proactive)
06:46PM	Ryoncil Sales Increase 60% in December Quarter to US$35.1M (GlobeNewswire)
Jan-01-26 06:02PM	Mesoblast Announces Changes to Board of Directors' Leadership Roles (GlobeNewswire)
Dec-29-25 06:57PM	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line (GlobeNewswire)
11:53AM	Loading…
Dec-16-25 11:53AM	Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy (PR Newswire)
Dec-15-25 12:35PM	Mesoblast (MESO) Sees Optimism From Analysts (Insider Monkey)
Dec-11-25 06:22PM	Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD (GlobeNewswire)
Dec-03-25 06:10PM	Mesoblast Participation at Piper Sandler Conference (GlobeNewswire)
Nov-24-25 06:39PM	Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil Revenue (GlobeNewswire)
Nov-20-25 06:32PM	Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids (GlobeNewswire) +7.33%
Nov-17-25 01:52AM	James M. O'Brien Appointed Chief Financial Officer at Mesoblast (GlobeNewswire)
Nov-10-25 09:55AM	Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now (Zacks)
Nov-04-25 06:40PM	Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation (GlobeNewswire)
Oct-29-25 12:00PM	All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy (Zacks)
Oct-19-25 07:48PM	Ryoncil Net Revenues Increase 69% in Second Quarter Post Launch (GlobeNewswire)
Oct-16-25 04:33PM	Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement (Insider Monkey) -5.64%
Oct-06-25 07:24PM	Ryoncil Revenues Increase 66% in Second Quarter Post Launch (GlobeNewswire) -5.92%
Oct-02-25 09:04PM	Ryoncil Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access (GlobeNewswire) +8.17%
Oct-01-25 01:46PM	Mesoblast Limited (MESO)'s Ryoncil Gains U.S.-Origin Status, Avoids Import Tariffs (Insider Monkey)
01:49AM	Loading…
Sep-26-25 01:49AM	Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs (GlobeNewswire)
Sep-14-25 09:18PM	Successful Commercial Launch of Ryoncil Highlighted at Global Healthcare Conferences (GlobeNewswire)
Sep-03-25 09:47PM	Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes (GlobeNewswire)
Aug-28-25 08:24PM	Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil (GlobeNewswire) -13.29%
Aug-27-25 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-17-25 01:51AM	Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating (Insider Monkey)
Jul-28-25 10:08AM	Mesoblast Limited (MESO) Launches First Cell Therapy for Children (Insider Monkey)
Jul-22-25 12:00PM	Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know (Zacks)
Jul-17-25 08:38PM	Successful Commercial Launch of Ryoncil (GlobeNewswire) +8.72% +26.58%
Jun-30-25 08:36PM	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure (GlobeNewswire) +11.29%
Jun-29-25 01:28PM	Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil (Insider Monkey)
Jun-11-25 09:24PM	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD (GlobeNewswire) -6.61%
May-27-25 09:14AM	Which S&P 500 Move Matters? (Motley Fool)
May-14-25 10:57PM	FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil (GlobeNewswire)
May-05-25 02:44AM	Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials (Seeking Alpha) -6.22%
Apr-29-25 08:53PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 (GlobeNewswire)
Apr-28-25 07:44PM	Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board (GlobeNewswire)
Apr-16-25 09:20PM	Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-03-25 06:58PM	Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs (GlobeNewswire) -8.88%
Apr-02-25 07:15PM	Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure (GlobeNewswire)
Mar-30-25 07:39PM	First Three Children to Commence Treatment With Ryoncil (GlobeNewswire)
Mar-26-25 08:19PM	Ryoncil is Now Available for Purchase in the United States (GlobeNewswire)
Mar-13-25 07:42PM	Ryoncil Product Information Now Available in All Four Major Drug Pricing Compendia in United States (GlobeNewswire)
Mar-12-25 07:30AM	Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall (GlobeNewswire)
Mar-06-25 06:54PM	Mesoblast Added to S&P/ASX 200 INDEX (GlobeNewswire) -7.69%
Feb-26-25 05:30PM	Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter (GlobeNewswire)
Feb-25-25 06:13PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-23-25 06:33PM	Dr. Gregory George MD PhD Joins Mesoblast Board (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 06:37PM	Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings (GlobeNewswire)
Jan-30-25 07:11PM	Ryoncil Commercial Launch Update and Product Pipeline (GlobeNewswire)
06:20PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 (GlobeNewswire)
Dec-19-24 04:21PM	Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval (Investor's Business Daily) +36.82% -12.71%
Dec-18-24 07:08PM	Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy (GlobeNewswire)
07:30AM	Mesoblast to be Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-05-24 06:29AM	Mesoblasts Revascor Therapy Shows Promise in Heart Failure (TipRanks)
Dec-04-24 06:32PM	FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease (GlobeNewswire)
Dec-02-24 06:20PM	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation (GlobeNewswire)
Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)
Aug-27-24 07:25PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Jul-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024 (GlobeNewswire)
Jul-23-24 07:53AM	FDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire) +9.54%
Jul-21-24 08:45PM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain (GlobeNewswire)
Jul-08-24 08:37PM	Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) (GlobeNewswire)
Jul-02-24 08:04AM	Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates (Zacks)
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
01:55AM	Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week (GlobeNewswire)
Jun-02-24 08:23PM	Mesoblast Corporate Presentation at Investor Conference (GlobeNewswire)
Apr-29-24 09:05PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 (GlobeNewswire) +13.78% -7.04%
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-27-24 11:00AM	Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (Zacks) -11.20%
Mar-25-24 10:34PM	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (GlobeNewswire) +78.64%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Mar-13-24 07:30PM	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer (GlobeNewswire) -8.27%
Mar-10-24 07:54PM	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) (GlobeNewswire)
Mar-03-24 08:25AM	Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-28-24 05:57PM	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 (GlobeNewswire) -5.74%
Feb-26-24 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-14-24 07:46PM	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire) +5.96%
Jan-30-24 09:13PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023 (GlobeNewswire)
Jan-19-24 11:30AM	Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug (Zacks) +11.63%
Jan-18-24 06:36PM	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease (GlobeNewswire)
Nov-27-23 07:28AM	Mesoblast files applications with US FDA for HLHS therapy (Pharmaceutical Business Review)
Nov-26-23 06:56PM	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease (GlobeNewswire)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your FINVIZ experience